RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose ...
RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--A new study, published today in The New England Journal of Medicine (NEJM), showed that SPIRIVA ® HandiHaler ® (tiotropium bromide inhalation powder), a ...
RIDGEFIELD, Conn., September 16, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results